Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Expedited Programs for Drug Approvals
Pharmaceutical Executive’s Lisa Henderson interviews Todd Phillips, PharmD, of Cardinal Health Regulatory Sciences about FDA’s expedited programs and key elements to consider before using this pathway.
Related Content
